Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.

Závada J, Lunt M, Davies R, Low AS, Mercer LK, Galloway JB, Watson KD, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium.

Ann Rheum Dis. 2014 Jan;73(1):252-5. doi: 10.1136/annrheumdis-2012-203102. Epub 2013 May 5.

PMID:
23644671
2.

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.

Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, Watson KD, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium.

Rheumatology (Oxford). 2013 Jan;52(1):91-8. doi: 10.1093/rheumatology/kes350.

3.

Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.

Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM; British Society for Rheumatology Biologics Register.

Arthritis Care Res (Hoboken). 2012 Aug;64(8):1108-15. doi: 10.1002/acr.21663.

4.

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.

Mercer LK, Green AC, Galloway JB, Davies R, Lunt M, Dixon WG, Watson KD; British Society for Rheumatology Biologics Register Control Centre Consortium, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register.

Ann Rheum Dis. 2012 Jun;71(6):869-74. doi: 10.1136/annrheumdis-2011-200622. Epub 2012 Jan 12.

5.

Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.

Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM; British Society for Rheumatology Biologics Register.

J Rheumatol. 2012 Feb;39(2):240-6. doi: 10.3899/jrheum.110610. Epub 2011 Dec 15.

6.

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register.

Ann Rheum Dis. 2011 Oct;70(10):1831-4. doi: 10.1136/ard.2011.153536. Epub 2011 Jul 22.

7.

The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Watson KD, Lunt M; BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2011 Jul;50(7):1341-2. doi: 10.1093/rheumatology/ker146. Epub 2011 Apr 12. No abstract available.

8.

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register.

Ann Rheum Dis. 2011 Apr;70(4):583-9. doi: 10.1136/ard.2010.139774. Epub 2011 Feb 17.

9.

Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci.

Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD; Wellcome Trust Case Control Consortium; British Society for Rheumatology Biologics Register, Barton A.

Arthritis Rheum. 2011 Mar;63(3):645-53. doi: 10.1002/art.30130.

10.

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.

Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Symmons DP; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2011 Jan;50(1):124-31. doi: 10.1093/rheumatology/keq242. Epub 2010 Jul 31.

11.

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.

Hyrich KL, Watson KD, Lunt M, Symmons DP; British Society for Rheumatology Biologics Register (BSRBR).

Rheumatology (Oxford). 2011 Jan;50(1):117-23. doi: 10.1093/rheumatology/keq209. Epub 2010 Jul 29.

12.

No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Lunt M, Watson KD, Dixon WG; British Society for Rheumatology Biologics Register Control Centre Consortium, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register.

Arthritis Rheum. 2010 Nov;62(11):3145-53. doi: 10.1002/art.27660.

13.

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP; British Society For Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register.

Arthritis Care Res (Hoboken). 2010 Jun;62(6):755-63. doi: 10.1002/acr.20129. Erratum in: Arthritis Care Res (Hoboken). 2010 Oct;62(10):1514.

14.

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.

Dixon WG, Hyrich KL, Watson KD, Lunt M; BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register.

Ann Rheum Dis. 2010 Jun;69(6):1086-91. doi: 10.1136/ard.2009.120626. Epub 2010 May 5. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

15.

Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.

Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL; British Society for Rheumatology Biologics Register.

Arthritis Care Res (Hoboken). 2010 Mar;62(3):345-53. doi: 10.1002/acr.20104.

16.

The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis.

Harrison MJ, Davies LM, Bansback NJ, McCoy MJ, Verstappen SM, Watson K, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium.

Qual Life Res. 2009 Nov;18(9):1195-205. doi: 10.1007/s11136-009-9539-2. Epub 2009 Sep 24.

17.

Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.

Hyrich KL, Deighton C, Watson KD; BSRBR Control Centre Consortium, Symmons DP, Lunt M; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2009 Oct;48(10):1323-7. doi: 10.1093/rheumatology/kep242. Epub 2009 Aug 25.

18.

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.

Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP; British Society for Rheumatology Biologics Register.

Arthritis Res Ther. 2009;11(2):R52. doi: 10.1186/ar2670. Epub 2009 Apr 8.

19.

Different methods of balancing covariates leading to different effect estimates in the presence of effect modification.

Lunt M, Solomon D, Rothman K, Glynn R, Hyrich K, Symmons DP, Stürmer T; British Society for Rheumatology Biologics Register; British Society for Rheumatology Biologics Register Control Centre Consortium.

Am J Epidemiol. 2009 Apr 1;169(7):909-17. doi: 10.1093/aje/kwn391. Epub 2009 Jan 19.

20.

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR.

Ann Rheum Dis. 2009 Feb;68(2):209-15. doi: 10.1136/ard.2007.087288. Epub 2008 Apr 2.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk